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Abstract
 
Leukotriene B
 
4
 
 (LTB
 
4
 
) is a potent chemoattractant and activator of both granulocytes and mac-
rophages. The actions of LTB
 
4
 
 appear to be mediated by a specific G protein–coupled receptor
(GPCR) BLT1, originally termed BLT (Yokomizo, T., T. Izumi, K. Chang, Y. Takuwa, and
T. Shimizu. 1997. 
 
Nature.
 
 387:620–624). Here, we report the molecular cloning of a novel
GPCR for LTB
 
4
 
, designated BLT2, which binds LTB
 
4
 
 with a Kd value of 23 nM compared
with 1.1 nM for BLT1, but still efficiently transduces intracellular signaling. BLT2 is highly ho-
mologous to BLT1, with an amino acid identity of 45.2%, and its open reading frame is located
in the promoter region of the BLT1 gene. BLT2 is expressed ubiquitously, in contrast to
BLT1, which is expressed predominantly in leukocytes. Chinese hamster ovary cells expressing
BLT2 exhibit LTB
 
4
 
-induced chemotaxis, calcium mobilization, and pertussis toxin–insensitive
inhibition of adenylyl cyclase. Several BLT1 antagonists, including U 75302, failed to inhibit
LTB
 
4
 
 binding to BLT2. Thus, BLT2 is a pharmacologically distinct receptor for LTB
 
4
 
, and
may mediate cellular functions in tissues other than leukocytes. BLT2 provides a novel target
for antiinflammatory therapy and promises to expand our knowledge of LTB
 
4
 
 function. The
location of the gene suggests shared transcriptional regulation of these two receptors.
Key words: BLT • cloning • gene cluster • leukotriene • low-afﬁnity receptor
 
Introduction
 
Leukotriene B
 
4
 
 (LTB
 
4
 
;
 
1 
 
5[
 
S
 
],12[
 
R
 
]-dihydroxy-6,14-cis-
8,10-trans-eicosatetraenoic acid) is a metabolite of arachi-
donic acid and is one of the most potent activators of gran-
ulocytes and macrophages (1–3). LTB
 
4
 
 binds to a specific G
protein–coupled receptor (GPCR) named BLT and acti-
vates the Gi and G16 classes of G proteins (4) to inhibit
adenylyl cyclase and activate phospholipase C. Exposure to
LTB
 
4
 
 induces adhesion of granulocytes to endothelial cells,
degranulation of the lysosomal enzymes, generation of su-
peroxide, and transmigration of granulocytes, all important
in the host defense against foreign organisms. Overproduc-
tion of LTB
 
4
 
 is involved in inflammatory diseases including
psoriasis (5), bronchial asthma (6), rheumatoid arthritis (7),
inflammatory bowel diseases (8), and ischemic renal failure
(9). Mice lacking leukotriene production are deficient in
their response to some acute and chronic inflammatory
stimuli (10–13). Therefore, BLT antagonists are under de-
velopment as potent antiinflammatory drugs (14–17). BLT
antagonists have most recently been reevaluated as immun-
osuppressive agents for allograft rejection (18–20). We re-
cently reported the characterization of cDNA encoding
human BLT1 (originally termed BLT) isolated from HL-60
cells, and showed that BLT1 mRNA is highly expressed in
leukocytes, and to a much lesser extent in the other tissues
(21). BLT1s isolated from mouse (22, 23), guinea pig (24,
25) and rat (26) are highly homologous to hBLT1, with
amino acid identities of 
 
.
 
75% (27). During the course of
the analysis of the genomic structures of human and mouse
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Abbreviations used in this paper:
 
 ALXR, lipoxin A
 
4
 
 receptor; CHO,
Chinese hamster ovary; EST, expressed sequence tag; FPR, formyl pep-
tide receptor; FPRL, formyl peptide receptor–like; GPCR, G protein–
coupled receptor; HETE, hydroxyeicosatetraenoic acid; LTB
 
4
 
, leuko-
triene B
 
4
 
; LX, lipoxin; ORF, open reading frame; PTX, pertussis toxin;
TM, transmembrane domain. 
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4
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BLT1, we identified a novel gene encoding a putative
GPCR with structural similarity to BLT1. Surprisingly, this
receptor shows specific binding for LTB
 
4
 
 and activates
multiple intracellular signaling pathways when expressed in
mammalian cells. In this study, we describe the molecular
cloning of this novel LTB
 
4
 
 receptor and demonstrate its
specificity, expression, and function. Further, we show that
the receptor has pharmacological properties different from
those of BLT1. In an accompanying paper, we report that
BLT2 open reading frame (ORF) is present in the pro-
moter region of BLT1 (28), weaving these two receptors
tightly at the genomic and functional level.
 
Materials and Methods
 
Isolation of Genomic Clones Containing Human and Mouse BLT1.
 
Genomic libraries from human and mouse were screened by
plaque hybridization. 10
 
6
 
 clones from human genomic library
(Human Lymphocyte Genomic Library; Stratagene), and
mouse library (129SV Mouse Genomic Library; Stratagene)
were lifted to Hybond N
 
1
 
 nylon membranes (Amersham
Pharmacia Biotech) and screened with [
 
32
 
P]dCTP-labeled
ORF of hBLT1 and 800 bp of expressed sequence tag (EST)
clones encoding mouse BLT1 (sequence data available from
EMBL/GenBank/DDBJ under accession no. AA028322), re-
spectively. Hybridization was carried out in a hybridization buffer
containing 6
 
3
 
 SSC, 10
 
3
 
 Dehnhart’s solution, 0.5% SDS, and
100 
 
m
 
g/ml single-stranded salmon sperm DNA at 65
 
8
 
C over-
night. The membranes were washed in 2
 
3
 
 SSC, 0.1% SDS, fol-
lowed by washing in 0.5
 
3 
 
SSC, 0.1% SDS at 25
 
8
 
C. Tertiary
screening gave three human and two mouse clones, which were
analyzed by Southern blotting. DNA sequencing was done using
an automated DNA sequencer (model 373A; Applied Biosystems)
and LI-COR 4000LS (Aloka).
 
Northern Blotting.
 
Human multiple-tissue Northern blots
(CLONTECH Laboratories, Inc.) were hybridized with [
 
32
 
P]
dCTP-labeled ORF of hBLT2 and human 
 
b
 
-actin cDNA in Ex-
pressHyb hybridization solution (CLONTECH Laboratories,
Inc.) for 18 h (BLT2) or 1 h (
 
b
 
-actin) at 68
 
8
 
C. The membranes
were washed in 0.1
 
3 
 
SSC, 0.1% SDS for 2 h at 65
 
8 
 
C and sub-
jected to autoradiography.
 
Construction of Expression Vectors for hBLT2.
 
Two expression
vectors for wild-type and hemagglutinin (HA)-tagged hBLT2 were
constructed. The inserts were amplified from the genomic clone
containing a full-length BLT2 by PCR with sense (5
 
9
 
-CGG-
GATCCCGCCATGTCGGTCTGCTACCGT-3
 
9
 
 and 5
 
9
 
-CGG-
GATCCCGCCATGTACCCCTACGACGTGCCCGACTACG-
CCTCGGTCTGCTACCGTCC-3
 
9 
 
for wild-type and HA,
respectively) and antisense (5
 
9
 
-GGAATTCAAAGGTCCCAT-
TCCGG-3
 
9
 
) primers, digested with BamHI and EcoRI, and sub-
cloned into pcDNA3 vector (Invitrogen). The plasmids for wild-
type and HA-tagged BLT2 were designated as phBLT2 and
pHA-hBLT2, respectively. Entire sequences of the inserts were
determined on both strands for unexpected misincorporations.
 
Cell Culture and Transfection.
 
HEK 293 and Chinese hamster
ovary (CHO) cells were cultured in DMEM and Ham’s F12, re-
spectively, supplemented with 10% FCS (Sigma-Aldrich), 100
IU/ml penicillin, and 100 
 
m
 
g/ml streptomycin. For transient ex-
pression, HEK 293 cells on 15-cm plates were transfected by li-
pofection using 20 
 
m
 
g of plasmid DNA and Lipofectamine Plus
(Life Technologies) according to the manufacturer’s protocol.
After 3 d, the cells were harvested and sonicated in a sonication
 
buffer containing 20 mM Tris-HCl, pH 7.4, 0.25 M sucrose, 10
mM MgCl
 
2
 
, 2 mM EDTA-Na
 
2
 
, 2 mM PMSF, and 1 
 
m
 
M pepsta-
tin-A. After centrifugation at 12,000 
 
g
 
 for 10 min at 4
 
8
 
C, the re-
maining supernatants were further centrifuged at 105,000 
 
g
 
 for 60
min. The resulting pellets were used for binding assay as mem-
brane fractions. The concentrations of the protein were deter-
mined by a method of Bradford using protein assay (Bio-Rad
Laboratories). For stable expression of HA-tagged BLT2, CHO-
K1 cells were transfected with pHA-hBLT2 by lipofection using
Transfectam (Life Technologies) and selected with 1 mg/ml
G418. 18 resistant clones were isolated by limiting dilution and
examined for the expression of the receptor protein. The cells
were fixed with PBS(
 
2
 
) containing 0.5% paraformaldehyde for 5
min on ice and blocked with PBS(
 
2
 
) containing 2% FCS. The
cells were bound with 10 
 
m
 
g/ml anti-HA antibody (clone CA12-5;
Eastman Kodak Co.) in PBS(
 
2
 
) containing 2% FCS for 1 h, fol-
lowed by staining with 500
 
3
 
 FITC-anti–mouse IgG (Zymed
Laboratories) for 30 min. The cells were washed twice with
PBS(
 
2
 
) and analyzed with a flow cytometer (Epics XL; Beckman
Coulter). Three lines of the cells (HA-12, -13, and -14) with
high expression were selected, maintained in Ham F12, 10%
FCS, and 0.3 mg/ml G418, and used for the further analyses.
 
3
 
H–LTB
 
4
 
 Binding Assay.
 
The membrane fractions of HEK
293 cells were examined for 
 
3
 
H–LTB
 
4
 
 binding. The binding
mixture (100 
 
m
 
l) contained membrane fractions and various con-
centrations of 
 
3
 
H–LTB
 
4
 
 with or without unlabeled LTB
 
4
 
 in bind-
ing buffer (50 mM Tris-HCl, pH 7.4, 10 mM MgCl
 
2
 
, 10 mM
NaCl, and 0.05% BSA). For determination of the nonspecific
binding, at least 1,000 times concentration of unlabeled LTB
 
4
 
 was
used. The mixtures were incubated at room temperature for 60
min with agitation, followed by rapid filtration through GF/C fil-
ters (Packard Instrument Co.) and washing with 
 
z
 
3 ml of bind-
ing buffer. The radioactivities of the filters were determined with
a scintillation counter (Top Count; Packard Instrument Co.).
 
Measurement of Intracellular Calcium Concentration.
 
The CHO
cells were loaded with 10 
 
m
 
M Fura-2 AM (Dojin) in Hepes-
Tyrode’s BSA buffer (25 mM Hepes-NaOH, pH 7.4, 140 mM
NaCl, 2.7 mM KCl, 1.0 mM CaCl
 
2
 
, 12 mM NaHCO
 
3
 
, 5.6 mM
 
d
 
-glucose, 0.37 mM NaH
 
2
 
PO
 
4
 
, 0.49 mM MgCl
 
2
 
, and 0.1% [wt/
vol] fatty acid–free BSA; Fraction V) at 37
 
8
 
C for 2 h. The cells
were washed twice and resuspended in Hepes-Tyrode’s BSA
buffer at the density of 10
 
6
 
 cells/ml. 0.5 ml of the cell suspension
was applied to a CAF-100 system (Jasco), and 5 
 
m
 
l of ligand solu-
tion in ethanol (for eicosanoids) or in PBS (for chemokines) was
added. Intracellular Ca
 
2
 
1
 
 concentration was measured by the ra-
tio of emission fluorescence of 500 nm by excitation at 340 and
380 nm.
Figure 1. (continues on facing page). 
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Figure 1. Cloning of human and mouse BLT2.
(A) Structures of human and mouse genomic
DNAs containing BLT1 and BLT2. In the hu-
man gene, transcribed segments are indicated by
open boxes, and putative ORFs are indicated
by filled boxes. (B) Primary structure of hBLT2
cDNA and deduced amino acid sequence. Pu-
tative TMs are boxed. An in-frame-stop codon
(TAG) is indicated by number signs at the 59
untranslated region of the putative ORF. The
positions of introns are shown by the nucleotide
numbers of introns. The incomplete polyade-
nylation signal (AATACA) is underlined. (C)
Sequence alignment of BLT1 and BLT2 from
humans and mice. Asterisks indicate amino ac-
ids conserved among four receptors. Dots indi-
cate amino acids conserved among three recep-
tors. The putative TMs of hBLT2 predicted
from a Kyte-Doolittle hydrophobicity analysis
are lined and labeled as I–VII. These sequence
data are available from EMBL/GenBank/DDBJ
under accession nos. AB029892 and AB029893. 
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Measurement of cAMP.
 
The cells were seeded on 96-well
plates (20,000 cells per well) and cultured for another 36 h. The
medium was replaced to 100 
 
m
 
l of Hepes-Tyrode’s BSA buffer
containing 1 mM IBMX (3-isobutyl-1-methylxanthine), and in-
cubated at 37
 
8
 
C for 20 min. The reaction was initiated by adding
100 
 
m
 
l of the ligand solution, and after 30 min of incubation, the
reaction was terminated by adding 25 
 
m
 
l of lysis reagent 1A in-
cluded in Biotrak cAMP enzyme immunoassay system (Amer-
sham Pharmacia Biotech). The cAMP contents in 5 
 
m
 
l of the ali-
quots were determined using the assay kit according to the
manufacturer’s protocol.
 
Chemotaxis Assay.
 
CHO cells expressing hBLT1 or hBLT2
were examined for their chemotactic responses as described pre-
viously (21).
 
Presentation of the Data.
 
All figures shown contain representa-
tive data from at least two independent experiments with similar
results. 
 
Results
 
Cloning of Human and Mouse BLT2.
 
During the course
of the analysis of human and mouse BLT1 genes, we iden-
tified an ORF encoding a putative seven-transmembrane–
type receptor with sequence similarities to BLT1. We
designate the new gene BLT2. BLT1 and BLT2 genes are
located within 10 kbp of each other both in humans and
mice (Fig. 1 A). Because a NotI site is present in the ORF
of hBLT2, we could not isolate full-length cDNA clones
for hBLT2 from cDNA libraries (data not shown). How-
ever, we found several EST clones containing polyadenyla-
tion signals followed by poly A tails, or exon/intron junc-
tions upstream of the ORF of hBLT2 (Fig. 1 B). The
ORFs of human and mouse BLT2 encode proteins with
358 and 360 amino acids, respectively (Fig. 1 C), which
contain several consensus GPCR sequences (29). These in-
clude 38N in the transmembrane domain (TM)-1; 38D in
TM-2; 146W and 155P in TM-4; 237W, 239P, and 244N
in TM-6; 284N, 285P, and 288Y in TM-7; and 94C and
168C, which may be joined by a disulfide bond. The
amino acid identity between human and mouse BLT2 was
 
92.7%. A blast search showed that hBLT2 is highly homol-
ogous to human and mouse BLT1, with the amino acid
identities of 45.2 and 44.6%, respectively. The similarity
between BLT1 and BLT2 was high in the putative TMs,
especially in TM-2, -3, and -7. Although BLT2 also
showed significant homology to an orphan GPCR (GPR25
[30]) and a recently-cloned chemoattractant receptor–homol-
ogous molecule expressed on TH2 cells (CRTH2 [31,
32]), the homology was much lower (
 
,31%) than that for
BLT1.
Tissue Distribution of BLT2. Searching EST database
revealed that BLT2 mRNA is expressed in various human
tissues, including skeletal muscle, heart, lung, and mamma-
lian gland. Northern blot analyses showed that BLT2
mRNA is expressed most abundantly in spleen, followed
by liver, ovary, and leukocytes, with weak signals detected
in most human tissues (Fig. 2). The size of the major tran-
script is 2.5 kb in these tissues, but longer transcripts are
also detected. The results show that BLT2 expression is dis-
tinct from BLT1, which is expressed almost exclusively in
leukocytes (21). BLT2 mRNA is also present in several hu-
man cell lines, including undifferentiated HL-60, K562,
MOLT-4, SW-480, and A549 cells, but the size of these
transcripts is much longer than those of the human tissues
(Fig. 2).
Characterization of hBLT2 as a Pharmacologically Distinct
LTB4 Receptor. Because sequence similarities between
BLT1 and BLT2 suggested that BLT2 is also a receptor for
eicosanoids, we examined 3H–LTB4 binding to the mem-
brane fractions of HEK 293 cells transiently transfected
with an hBLT2 expression construct. We chose HEK 293
cells for transfection because they showed no specific bind-
ing for 3H–LTB4 at concentrations of up to 5 nM (data not
shown). Membrane fractions of HEK 293 cells expressing
hBLT2 showed a specific and saturable LTB4 binding,
whereas those of empty vector-transfected cells did not
(Fig. 3 A). Scatchard analysis revealed that the Kd value of
hBLT2 for LTB4 was 22.7 nM (Fig. 3, B and C), which
was 20-fold higher than that of hBLT1 (1.1 nM; data not
Figure 2. Northern blot analyses of
BLT2 mRNA in various human tissues and
cells. Human multiple-tissue Northern blot
filters (2 mg poly-A RNA/lane; CLON-
TECH Laboratories, Inc.) were hybridized
with [32P]dCTP-labeled ORF of hBLT2 or
human b-actin cDNA (CLONTECH Lab-
oratories, Inc.).425 Yokomizo et al.
shown). We next examined the inhibition of 3H–LTB4
binding by two distinct BLT1 antagonists and various
eicosanoids, using the membrane fractions of HEK 293
cells transfected with hBLT1 or hBLT2. Although 3H–
LTB4 binding to hBLT1 was inhibited by both ONO 4057
and U 75302, 3H–LTB4 binding to hBLT2 was not inhib-
ited by U 75302 (Fig. 3, D and E). Several other BLT an-
tagonists also failed to inhibit LTB4 binding to BLT2 (data
not shown). 3H–LTB4 binding to BLT2 was competed
with 5 mM LTB4 (100%) or 20-hydroxy LTB4 (78.6 6
4.4% compared with the competition by LTB4). 20-car-
boxy-LTB4, lipoxin (LX)A4, LXB4, or 5-oxo-eicosatet-
raenoic acid slightly (,40%) competes with 5 nM 3H–
LTB4 binding to BLT2 at the concentration of 5 mM.
These results clearly show that BLT2 is a pharmacologically
distinct receptor from BLT1 (21).
Intracellular Signaling of BLT2. To examine whether the
binding of LTB4 to BLT2 transduces intracellular signaling,
Figure 3. Binding of 3H–LTB4 to the membrane fractions of HEK 293
cells transiently transfected with hBLT1 or hBLT2. (A) Binding of 5 nM
3H–LTB4 to the membrane fractions (20 mg of protein) from HEK 293
cells transfected with control vector (Vector), BLT1 expression vector
(hBLT1), or BLT2 expression vector (hBLT2). Total binding (black col-
umns) and nonspecific binding (white columns) are presented (mean 6
SD, n 5 3). d.p.m., disintegration per minute. (B and C) Binding iso-
therms (B) and Scatchard analysis (C) of 3H–LTB4 binding to membrane
fractions of HEK 293 cells transfected with hBLT2. In B, total binding
(h), nonspecific binding (s), and specific binding (d) are presented
(mean  6  SD, n 5 3). (D and E) Inhibition of 5 nM 3H–LTB4 binding to
the membrane fractions (20 mg of protein) of HEK 293 cells transfected
with hBLT2 (d) or hBLT1 (s) by two BLT antagonists, (F) ONO 4057
and (G) U 75302 (mean 6 SD, n 5 3).
Figure 4. Calcium mobilization in CHO-hBLT1 and CHO-hBLT2
cells by LTB4. (A) Increases in intracellular calcium after exposure to var-
ious concentrations of LTB4 were measured in CHO-hBLT1 (s) and
CHO-hBLT2 (d) cells, and were represented as percentages of the max-
imum responses. The inset graph shows absolute values of increase in in-
tracellular calcium concentrations (mean 6 SD, n 5 3). (B) Effects of
PTX pretreatment on LTB4-induced increases in intracellular calcium
concentrations in CHO-hBLT2 cells. The cells were pretreated with 100
ng/ml PTX (s) or vehicle (d) for 12 h. The inset shows increases in in-
tracellular calcium concentrations, evoked by 2 U/ml thrombin, that
were not affected by PTX pretreatment (mean 6 SD, n 5 3).426 Novel Leukotriene B4 Receptor
we established several lines of CHO cells stably expressing
BLT2 (CHO-hBLT2) and compared LTB4-induced cellu-
lar effects to those obtained with CHO cells expressing
hBLT1 (CHO-hBLT1 [21]). CHO-K1 cells were trans-
fected with an expression vector for HA-tagged hBLT2,
selected with G418, and examined for expression of the
tagged receptor using an anti-HA antibody. 18 clones were
picked by limiting dilution, and 3 representative clones
with high HA expression were selected (data not shown).
As each of these three clones showed LTB4-induced cal-
cium mobilization and chemotaxis, we chose one clone as a
representative and analyzed the LTB4-induced intracellular
signaling in more detail.
Fig. 4 A shows the increases in intracellular calcium con-
centrations induced by LTB4 in CHO-hBLT1 and CHO-
hBLT2 cells. In both cells, LTB4 increased intracellular
calcium in a dose-dependent manner, but the maximum
increase in CHO-hBLT2 cells was only one third of that in
CHO-hBLT1 cells (Fig. 4 A, inset). The dose response
curve for LTB4 in CHO-hBLT2 cells was right shifted
from that in CHO-hBLT1 cells by 2 orders of magnitude
(Fig. 4 A). Other ligands, including leukotriene C4, leuko-
triene D4, leukotriene E4, 5(S)-hydroxyeicosatetraenoic acid
(HETE), 5(R)-HETE, 12(S)-HETE, 12(R)-HETE, 15(S)-
HETE, 15(R)-HETE, 5-oxo-eicosatetraenoic acid, LXA4,
LXB4, IL-8, C5a (a component of complement), and
FMLP, were not able to induce any significant change in
intracellular calcium in CHO-hBLT2 cells at the concen-
trations of up to 1 mM (data not shown). 20-hydroxy-
LTB4, which partially inhibited 3H–LTB4 binding to
BLT2, did not induce any change in intracellular calcium
in CHO-hBLT2 at 1 mM (data not shown). To determine
the subtypes of G protein(s) responsible for calcium in-
crease by BLT2, we pretreated CHO-hBLT2 cells with
100 ng/ml pertussis toxin (PTX) for 12 h and examined
the intracellular calcium response. Pretreatment of the cells
with PTX diminished by half the response in CHO-
hBLT2 cells (Fig. 4 B). PTX pretreatment of these cells did
not affect the intracellular calcium increases induced with 2
U/ml thrombin (Fig. 4 B, inset), but completely abolished
LTB4-induced cell migration (see Fig. 6 B) in CHO-
hBLT2 cells. Therefore, we conclude that the calcium re-
sponse mediated by hBLT2 involves both PTX-sensitive
and -insensitive G protein(s) in CHO cells.
We next examined the effects of LTB4 stimulation on
adenylyl cyclase activity in these cells by measuring the
cAMP accumulation. In the absence of forskolin, which
activates adenylyl cyclases, no increase in cAMP concentra-
tion was observed either in CHO-hBLT1 or CHO-hBLT2
cells (data not shown). On the other hand, LTB4 inhibited
50 mM forskolin-activated adenylyl cyclase activities in a
dose-dependent manner in both CHO-hBLT1 and CHO-
hBLT2 cells. The IC50 value of LTB4 for inhibiting adeny-
lyl cyclase activities in CHO-hBLT2 cells (80 nM; Fig. 5
A) was higher than that of CHO-hBLT1 cells (0.1 nM;
Fig. 5 A). Pretreatment of the cells with 100 ng/ml PTX
for 12 h had markedly different effects on LTB4-induced
adenylyl cyclase inhibition. Although PTX pretreatment
abolished z80% of LTB4-induced adenylyl cyclase inhibi-
tion in CHO-hBLT1 cells, the same pretreatment had a
negligible effect on cAMP accumulation in CHO-hBLT2
cells (Fig. 5, B and C). These results indicate that BLT2
uses Gz, a PTX-insensitive G protein (33, 34), in inhibiting
adenylate cyclases.
LTB4 is a potent chemoattractant of granulocytes and
macrophages, and CHO cells migrate toward LTB4 when
transfected with BLT1 (21). Examining the chemotactic
activities of LTB4 mediated by BLT2 using CHO-hBLT2
Figure 5. Cyclic AMP accumulation in forskolin-treated CHO-hBLT1 and
CHO-hBLT2 cells. (A) LTB4 inhibits 50 mM forskolin–induced adenylyl cyclase
activities in both CHO-hBLT1 (s) and CHO-hBLT2 (d) cells. Forskolin-
induced cAMP levels in the absence of LTB4 were 44.2 6 4.5 pmol/well in CHO-
hBLT2 and 112.0 6 11.8 pmol/well in CHO-hBLT1 cells (mean 6 SE, n 5 4).
(B) The effects of PTX pretreatment (100 ng/ml, 12 h) on cAMP accumulation
in CHO-hBLT2 cells. The 50 mM forskolin–induced cAMP levels in the ab-
sence of LTB4 were 44.2 6 4.5 pmol/well in untreated cells and 48.3 6 4.9
pmol/well in PTX-treated cells (mean 6 SE, n 5 4). (C) The effects of PTX
pretreatment (100 ng/ml, 12 h) on cAMP accumulation in CHO-hBLT1 cells. The 50 mM forskolin–induced cAMP levels in the absence of LTB4 were
112.0 6 11.8 pmol/well in untreated cells and 71.0 6 7.3 pmol/well in PTX-treated cells (mean 6 SE, n 5 4).427 Yokomizo et al.
cells, both CHO-hBLT1 and CHO-hBLT2 cells showed
potent chemotactic activities, with bell-shaped dose re-
sponse curves (Fig. 6 A). The optimum concentration of
LTB4 needed for chemotaxis in CHO-hBLT2 cells was
higher than that of CHO-hBLT1 cells by 2 orders of mag-
nitude, enhancing further the idea that hBLT2 is a low-
affinity but still potent chemotactic receptor for LTB4. As
shown in Fig. 6 B, chemotaxis of CHO-hBLT2 cells in-
duced by LTB4 was abolished by PTX, showing that PTX-
sensitive G protein(s) are absolutely required for LTB4-
induced cell migration through BLT1 and BLT2.
Discussion
LTB4 is one of the most potent chemoattractants for leu-
kocytes, and is unique because it is a lipid mediator biosyn-
thesized from membrane phospholipids by the actions of
cytosolic phospholipase A2 (35, 36), 5-lipoxygenase, and
LTA4 hydrolase (3, 37). LTB4–BLT interaction plays im-
portant roles in host defense mechanism and inflammatory
diseases. Mice lacking in leukotriene production are insen-
sitive to some inflammatory stimuli, and mice overexpress-
ing BLT1 exhibit enhanced responses to infections and
lung ischemic-reperfusion injury (38). Numerous bio-
chemical and pharmacological studies indicated that high-
affinity and LTB4-specific receptors exist in membranes of
neutrophils, macrophages, eosinophils, and T cells. Al-
though many antagonists for LTB4 receptor are under de-
velopment, their main target has been directed to the high-
affinity receptor for LTB4, BLT1. There are also reports of
low-affinity binding protein(s) for LTB4 in human granulo-
cytes (39), murine spleen (15), and guinea pig alveolar and
peritoneal eosinophils (40, 41). Some investigators have
speculated that the high-affinity receptor mediates chemo-
taxis for LTB4, and the low-affinity receptor mediates
LTB4-induced secretary and oxidase-activation responses
(42). Therefore, we have had only suggestive information
on a low-affinity LTB4 receptor.
Identification of a Novel GPCR, BLT2, in a Gene Cluster
with BLT1. Our interest in understanding the molecular
mechanisms that regulate the transcription of BLT1 (origi-
nally termed BLT) gene led us to isolate several genomic
clones containing BLT1 gene from humans and mice. The
precise structure of the hBLT1 gene and the mechanism by
which the BLT1 gene is regulated is published in an ac-
companying paper (28). During the course determining the
nucleotide sequences of these genomic clones, we discov-
ered an ORF for a putative seven-transmembrane receptor
(BLT2) that is similar to BLT1 (Fig. 1, A and B). Human
and mouse BLT2 genes encode proteins of 358 and 360
amino acids, respectively (Fig. 1 C), similar to hBLT1 (352
amino acids). The amino acid identity of hBLT1 and
hBLT2 is 45.2%, and that of human and mouse BLT2 is
92.7%. The amino acid identity of BLT2 between human
and mouse is higher than BLT1 between two species
(78.6%), suggesting that BLT2 has been conserved during
evolution and must therefore play an important role. We
conclude that BLT2 is not a pseudogene based on the fol-
lowing criteria: (a) Northern blotting showed that mRNA
expression is seen in various tissues and cells in humans; (b)
the primary structures of human and mouse BLT2 are well
conserved, with the amino acid identity of 92.7%; (c) the
structures of genomic clones containing BLT1 and BLT2
are similar both in humans and mice; (d) there are no frame
shifts in either human or mouse BLT2 ORF; and (e) many
EST clones encoding BLT2 have been deposited in the
EMBL/GenBank/DDBJ database. hBLT2 showed a signif-
icant homology to a recently cloned chemoattractant re-
ceptor–homologous molecule expressed on TH2 cells (31,
32) and an orphan GPCR, GPR25 (30), with amino acid
identities of 30.5 and 28.5%, respectively. A recently
cloned receptor for cysyteinyl leukotrienes, Cys-LT1,
showed 28% amino acid identity to hBLT1 (43, 44). Thus,
BLT2 is the second member for a LTB4 receptor family.
Figure 6. LTB4-induced cell migration in CHO-hBLT1 and CHO-
hBLT2 cells. (A) Dose dependency of LTB4-induced cell migration was
measured in CHO-hBLT1 (s), CHO-hBLT2 (d), and CHO vector (n)
cells (mean 6 SE, n 5 4). (B) Effects of PTX pretreatment (100 ng/ml,
12 h) on LTB4-induced cell migration in CHO-hBLT2 cells (mean 6
SE, n 5 4).428 Novel Leukotriene B4 Receptor
hBLT1 was reported to be located on human chromo-
some 14q11.2-q12 (45), and our present finding shows that
the ORF for hBLT2 is located at 3 kbp upstream of hBLT1
ORF (Fig. 1 A). Similar gene clusters of GPCRs have been
reported for the FMLP receptor, its related receptors (46),
and C5a receptor on chromosome 19q13.3-q13.4 (47), and
for CXCR1 and 2, the receptors for IL-8, on 2q34-q35
(48–50). b2 and a1 adrenergic receptors are also closely
linked on human chromosome 5q32-q34, and b1 and a2
adrenergic receptors are both located on human chromo-
some 10q24-q26 (51). Formyl peptide receptor (FPR)-like
(FPRL) 1–LXA4 receptor (AXLR), which is a neighboring
receptor to the FMLP specific receptor (FPR1), was re-
ported to respond to lipoxin A4 at nM (52) and the acute
phase protein serum amyloid A at mM (53). It was shown
recently that MHC binding peptide and synthetic peptide
MMK-1 bind to FPRL1/ALXR at sub-mM concentration
(54). In the case of IL-8 receptors, CXCR1 is a high-affin-
ity and specific receptor for IL-8, and CXCR2 is a less se-
lective receptor for IL-8, which also binds growth regula-
tory oncogene (GRO)-a, -b, -g and neutrophil-activating
peptide (NAP)-2 (55). These receptor clusters appear to be
generated by gene duplication, with the degree of homol-
ogy among the members of the cluster indicative of the
timing of the duplication during evolution (50). The amino
acid identity between hBLT1 and 2 (45.2%) is much lower
than that between CXCR1 and 2 (77%) and between
FPR1 and FPRL1/ALXR (72%), suggesting that the dupli-
cation event that generated BLT2 occurred earlier than the
events generating the other receptor clusters. The reasons
why these receptors for chemoattractants form clusters are
not yet clear, but may become evident as more information
is gathered. Surprisingly, the promoter region of BLT1 is
localized in the ORF of BLT2. This, to our knowledge, is
the first mammalian example of “promoter in ORF,”
which is reported in bacteria (56) and bacteriophages (57).
Characterization of BLT2 as a Low-Affinity Receptor for
LTB4. We first examined whether or not BLT2 can rec-
ognize LTB4. A binding assay using membrane fractions
from HEK 293 cells exogenously transfected with the re-
ceptor cDNA showed that BLT2 is a low-affinity receptor
for LTB4 (Fig. 3, A–E). The Kd value was 22.7 nM, which
is higher than that of BLT1 (21–26). High- and low-affin-
ity LTB4 binding sites were reported in human (42, 58) and
rabbit (59) neutrophils, differentiated HL-60 cells (60, 61),
guinea pig peritoneal eosinophils (41), and murine spleen
membrane (62). The Kd values of these low-affinity bind-
ing sites for LTB4 were reported to be between 70 and 580
nM, similar to the value obtained from the transfection
study using BLT2 (Fig. 3, B and C). Thus, BLT2 appears
to be a low-affinity binding site for LTB4. The high ex-
pression of BLT2 in spleen on Northern blots (Fig. 2) also
supports this speculation, as spleen is the tissue where the
low-affinity receptor is most well characterized (14, 15,
62). Studies using BLT antagonists showed that BLT2 is a
pharmacologically novel receptor for LTB4, as binding of
LTB4 to BLT2 was not inhibited by a classical BLT antag-
onist, U 75302 (references 21, 63; Fig. 3, D and E).
Signaling from BLT2. We next established several lines
of CHO cells stably expressing BLT2 to examine intracel-
lular signaling. CHO cells were transfected with an expres-
sion construct for HA-tagged BLT2 and were selected with
culture media containing G418, and stable clones were iso-
lated. All three cell lines selected for high HA expression
responded to LTB4 with calcium mobilization and chemo-
taxis, as opposed to cells transfected with the empty vector,
which did not respond. In calcium mobilization assays, IC50
values for LTB4 in CHO-hBLT1 and CHO-hBLT2 cells
were 10 nM and 300 nM, respectively (Fig. 4 A). Calcium
increases in CHO-hBLT1 cells were not inhibited by PTX
pretreatment (21), and cotransfection of BLT1 cDNA with
G16a, but not with G11a, increased LTB4-induced d-myo-
inositol 1, 4, 5-triphosphate (IP3) accumulation in Cos-7
cells (4). LTB4–BLT1 interaction appears to activate G16a
protein, leading to the activation of phospholipase C. On
the other hand, about half of the calcium increase by LTB4
through BLT2 was inhibited by pretreatment of PTX (Fig.
4 B), suggesting that different types and/or different ratios
of G proteins are activated by binding of LTB4 to BLT2.
Differences in the maximum responses in LTB4-induced
calcium mobilizations in CHO-BLT1 and CHO-BLT2
cells (Fig. 4 A, inset) also support this hypothesis. As the
low-affinity binding of LTB4 to BLT2 raised the possibility
of the other ligands for this receptor, we examined calcium
mobilization in CHO-BLT2 cells by various eicosanoids
and chemoattractants. Other than LTB4 (discussed in Re-
sults), none of the ligands tested showed positive responses
up to 1 mM, whereas 100 nM LTB4 showed a clear cal-
cium increase (Fig. 4).
With respect to inhibition of adenylyl cyclase, PTX pre-
treatment had different effects on these two related recep-
tors (Fig. 5 A). LTB4-mediated inhibition of adenylyl cy-
clase in CHO-hBLT1 cells is completely PTX sensitive,
but in CHO-hBLT2 it is hardly affected by PTX pretreat-
ment (Fig. 5, B and C), suggesting that BLT1 and BLT2
use different subtype(s) of Gi-like G proteins. Among Gi
family members with inhibitory effects on adenylyl cycla-
ses, only Gza is insensitive to PTX, as it lacks the Cys resi-
due at position (24) from the COOH terminus (33, 34).
Therefore, BLT2 may use Gza to inhibit adenylyl cyclase
in transfected CHO cells. On the other hand, LTB4-induced
chemotactic activities of CHO-hBLT1 and CHO-hBLT2
cells were completely PTX sensitive (Fig. 5 B). Thus BLT2,
like BLT1, uses at least three classes of G proteins (Gi,
Gq-like, and Gz) for signaling.
BLT2, a Possible Therapeutic Target. A unique charac-
teristic of BLT2 is its ubiquitous expression, with the high-
est mRNA levels in spleen, followed by liver, ovary, and
peripheral leukocytes (Fig. 2). In ovary, LTB4 was reported
to mediate ovulation in rat (64) and rabbit (65), without af-
fecting the production of estradiol and progesterone from
the ovarian cells. The biological roles of LTB4 in liver are
unknown, but the liver expresses the LTB4-producing en-
zyme LTA4 hydrolase (66, 67) and LTB4-degrading en-
zymes LTB4 20-hydroxylase (68, 69), LTB4 12-hydroxyde-
hydrogenase (70), and b-oxidizing enzymes (71). The liver429 Yokomizo et al.
also expresses high amounts of peroxisome proliferator-
activated factor (PPAR)a, a reported nuclear receptor for
LTB4, which controls transcription of various genes in-
volved in lipid metabolism (72, 73). Therefore, it is reason-
able to consider that LTB4 has some as yet unidentified
roles in the liver function that are mediated by BLT2.
Northern blotting shows that human peripheral leukocytes
express both BLT1 and BLT2 (Fig. 2; reference 21), which
agrees well with a previous report of the coexistence of
high- and low-affinity LTB4 receptors in these cells (39).
Some investigators have speculated that the high-affinity
receptor mediates chemotaxis for LTB4 and the low-affinity
receptor mediates LTB4-induced degranulation and super-
oxide anion generation (42). Transfection studies using
BLT1 or BLT2 or both will enable us to precisely analyze
and distinguish the roles of two receptors in vitro. We
should again emphasize that LTB4 binding to BLT2 is not
inhibited by most of the previously developed BLT antago-
nists, suggesting that BLT2 could be a therapeutic target for
novel drugs related to contraception and immunosuppres-
sion. The lack of significant effects of the current BLT an-
tagonists in some studies may be due to the lack of their ef-
fects on BLT2. Further study will be needed to clarify the
biological roles of LTB4 through BLT2, especially in rela-
tion to the spleen, and in ovaries and the liver. Although
LTB4 was the best ligand among those tested for hBLT2,
we should pay attention to the possible existence of better
ligand(s) for BLT2 than LTB4.
In conclusion, we have identified a second leukotriene
B4 receptor, BLT2, from humans and mice. The BLT2
gene closely located to the BLT1 gene in both humans and
mice. In an accompanying paper (28), we detail the pres-
ence of the ORF for BLT2 localized in the promoter re-
gion of BLT1. BLT2 is a low-affinity and pharmacologi-
cally novel receptor for LTB4, activating different G
protein(s) to increase intracellular calcium, inhibit adenylyl
cyclase, and stimulate chemotaxis. These findings may lead
us to identify other members of LTB4 receptor family, and
provide new important clues concerning the physiological
and pathophysiological roles of LTB4.
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